share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股sec公告 ·  05/29 07:38
Moomoo AI 已提取核心訊息
bluebird bio, Inc. has announced a significant change in its executive team with the departure of Christopher Krawtschuk as Chief Financial Officer and principal accounting officer, effective June 10, 2024. The company clarified that Krawtschuk's departure is not due to any disagreements on accounting policies or business strategy. Concurrently, the Board of Directors has appointed O. James Sterling as the new Chief Financial Officer, with his role also commencing on June 10, 2024. Sterling brings experience from his previous role as CFO of Renalytix plc and has held positions at Renwick Capital LLC and investment banks Brock Capital Group LLC and Aleutian Capital Group. His appointment comes with a comprehensive compensation package, including a $500,000 annual salary, a $100,000 sign-on bonus, a 45% target annual bonus, and an initial equity grant. The company has detailed the terms of Sterling's employment and severance provisions, as well as the severance arrangements for Krawtschuk, in line with his existing employment agreement.
bluebird bio, Inc. has announced a significant change in its executive team with the departure of Christopher Krawtschuk as Chief Financial Officer and principal accounting officer, effective June 10, 2024. The company clarified that Krawtschuk's departure is not due to any disagreements on accounting policies or business strategy. Concurrently, the Board of Directors has appointed O. James Sterling as the new Chief Financial Officer, with his role also commencing on June 10, 2024. Sterling brings experience from his previous role as CFO of Renalytix plc and has held positions at Renwick Capital LLC and investment banks Brock Capital Group LLC and Aleutian Capital Group. His appointment comes with a comprehensive compensation package, including a $500,000 annual salary, a $100,000 sign-on bonus, a 45% target annual bonus, and an initial equity grant. The company has detailed the terms of Sterling's employment and severance provisions, as well as the severance arrangements for Krawtschuk, in line with his existing employment agreement.
藍鳥生物公司宣佈,隨着克里斯托弗·克勞茨丘克辭去首席財務官兼首席會計官的職務,其執行團隊將進行重大變動,該職位將於2024年6月10日生效。該公司澄清說,Krawtschuk的離職不是由於會計政策或業務戰略上的任何分歧造成的。同時,董事會已任命 O. James Sterling 爲新任首席財務官,其職位也將於 2024 年 6 月 10 日開始。斯特林擁有之前擔任Renalytix plc首席財務官的經驗,曾在倫威克資本有限責任公司和投資銀行布羅克資本集團有限責任公司和阿留申資本集團任職。他的任命附帶了全面的薪酬待遇,包括50萬美元的年薪、100,000美元的簽約獎金、45%的目標年度獎金和初始股權補助。該公司根據斯特林現有的僱傭協議,詳細介紹了斯特林的僱傭和遣散費條款以及對Krawtschuk的遣散費安排。
藍鳥生物公司宣佈,隨着克里斯托弗·克勞茨丘克辭去首席財務官兼首席會計官的職務,其執行團隊將進行重大變動,該職位將於2024年6月10日生效。該公司澄清說,Krawtschuk的離職不是由於會計政策或業務戰略上的任何分歧造成的。同時,董事會已任命 O. James Sterling 爲新任首席財務官,其職位也將於 2024 年 6 月 10 日開始。斯特林擁有之前擔任Renalytix plc首席財務官的經驗,曾在倫威克資本有限責任公司和投資銀行布羅克資本集團有限責任公司和阿留申資本集團任職。他的任命附帶了全面的薪酬待遇,包括50萬美元的年薪、100,000美元的簽約獎金、45%的目標年度獎金和初始股權補助。該公司根據斯特林現有的僱傭協議,詳細介紹了斯特林的僱傭和遣散費條款以及對Krawtschuk的遣散費安排。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息